209 related articles for article (PubMed ID: 24615121)
1. Prognostic value of tissue and circulating levels of IMP3 in prostate cancer.
Szarvas T; Tschirdewahn S; Niedworok C; Kramer G; Sevcenco S; Reis H; Shariat SF; Rübben H; vom Dorp F
Int J Cancer; 2014 Oct; 135(7):1596-604. PubMed ID: 24615121
[TBL] [Abstract][Full Text] [Related]
2. Insulin-like growth factor II mRNA binding protein 3 (IMP3) is overexpressed in prostate cancer and correlates with higher Gleason scores.
Ikenberg K; Fritzsche FR; Zuerrer-Haerdi U; Hofmann I; Hermanns T; Seifert H; Müntener M; Provenzano M; Sulser T; Behnke S; Gerhardt J; Mortezavi A; Wild P; Hofstädter F; Burger M; Moch H; Kristiansen G
BMC Cancer; 2010 Jun; 10():341. PubMed ID: 20591150
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy.
Chromecki TF; Cha EK; Pummer K; Scherr DS; Tewari AK; Sun M; Fajkovic H; Roehrborn CG; Ashfaq R; Karakiewicz PI; Shariat SF
BJU Int; 2012 Jul; 110(1):63-8. PubMed ID: 22077633
[TBL] [Abstract][Full Text] [Related]
4. Comparison of mRNA, Protein, and Urinary Nucleic Acid Levels of S100A8 and S100A9 between Prostate Cancer and BPH.
Yun SJ; Yan C; Jeong P; Kang HW; Kim YH; Kim EA; Lee OJ; Kim WT; Moon SK; Kim IY; Choi YH; Kim WJ
Ann Surg Oncol; 2015 Jul; 22(7):2439-45. PubMed ID: 25348783
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic value of tissue and circulating levels of Ephrin-A2 in prostate cancer.
Li S; Wu Z; Chen Y; Kang Z; Wang H; He P; Zhang X; Hu T; Zhang Q; Cai Y; Xu X; Guan M
Tumour Biol; 2016 Apr; 37(4):5365-74. PubMed ID: 26561474
[TBL] [Abstract][Full Text] [Related]
6. PPM1D as a novel biomarker for prostate cancer after radical prostatectomy.
Jiao L; Shen D; Liu G; Jia J; Geng J; Wang H; Sun Y
Anticancer Res; 2014 Jun; 34(6):2919-25. PubMed ID: 24922655
[TBL] [Abstract][Full Text] [Related]
7. IMP3 is a novel prognostic marker that correlates with colon cancer progression and pathogenesis.
Li D; Yan D; Tang H; Zhou C; Fan J; Li S; Wang X; Xia J; Huang F; Qiu G; Peng Z
Ann Surg Oncol; 2009 Dec; 16(12):3499-506. PubMed ID: 19672661
[TBL] [Abstract][Full Text] [Related]
8. IMP3 accelerates the progression of prostate cancer through inhibiting PTEN expression in a SMURF1-dependent way.
Zhang X; Wang D; Liu B; Jin X; Wang X; Pan J; Tu W; Shao Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):190. PubMed ID: 32938489
[TBL] [Abstract][Full Text] [Related]
9. Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.
Huang L; Li M; Wang D; He J; Wu W; Zeng Q; Li J; Xiao M; Hu J; He Y; Li Y; Mai L; Liu W
Hum Pathol; 2016 Jan; 47(1):109-14. PubMed ID: 26546252
[TBL] [Abstract][Full Text] [Related]
10. High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer.
Szarvas T; vom Dorp F; Niedworok C; Melchior-Becker A; Fischer JW; Singer BB; Reis H; Bánkfalvi Á; Schmid KW; Romics I; Ergün S; Rübben H
BJU Int; 2012 Sep; 110(6 Pt B):E308-17. PubMed ID: 22500655
[TBL] [Abstract][Full Text] [Related]
11. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.
Hu S; Wu X; Zhou B; Xu Z; Qin J; Lu H; Lv L; Gao Y; Deng L; Yin J; Li G
J Cancer Res Clin Oncol; 2014 Jun; 140(6):883-93. PubMed ID: 24647926
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
13. Profiling of the calcitonin-calcitonin receptor axis in primary prostate cancer: clinical implications and molecular correlates.
Thakkar A; Bijnsdorp IV; Geldof AA; Shah GV
Oncol Rep; 2013 Sep; 30(3):1265-74. PubMed ID: 23820954
[TBL] [Abstract][Full Text] [Related]
14. Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma.
Tschirdewahn S; Panic A; Püllen L; Harke NN; Hadaschik B; Riesz P; Horváth A; Szalontai J; Nyirády P; Baba HA; Reis H; Szarvas T
Int J Cancer; 2019 Jul; 145(2):531-539. PubMed ID: 30650187
[TBL] [Abstract][Full Text] [Related]
15. Lower levels of nuclear beta-catenin predict for a poorer prognosis in localized prostate cancer.
Horvath LG; Henshall SM; Lee CS; Kench JG; Golovsky D; Brenner PC; O'Neill GF; Kooner R; Stricker PD; Grygiel JJ; Sutherland RL
Int J Cancer; 2005 Jan; 113(3):415-22. PubMed ID: 15455387
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
Zhang X; Wang Y; Ning Y
Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
[TBL] [Abstract][Full Text] [Related]
17. Tumor-specific Expression of Insulin-like Growth Factor II mRNA-binding Protein 3 Independently Predicts Worse Survival of Patients With Adenocarcinoma of the Ampulla of Vater.
Kim HG; Park MS; Sung JY; Kim YW; Kim HS; Na K
Anticancer Res; 2019 Sep; 39(9):4947-4955. PubMed ID: 31519600
[TBL] [Abstract][Full Text] [Related]
18. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study.
Jiang Z; Chu PG; Woda BA; Rock KL; Liu Q; Hsieh CC; Li C; Chen W; Duan HO; McDougal S; Wu CL
Lancet Oncol; 2006 Jul; 7(7):556-64. PubMed ID: 16814207
[TBL] [Abstract][Full Text] [Related]
19. Golgi phosphoprotein 3 expression predicts poor prognosis in patients with prostate cancer undergoing radical prostatectomy.
Zhang L; Guo F; Gao X; Wu Y
Mol Med Rep; 2015 Jul; 12(1):1298-304. PubMed ID: 25760033
[TBL] [Abstract][Full Text] [Related]
20. IMP3 Predicts Invasion and Prognosis in Human Lung Adenocarcinoma.
Yan J; Wei Q; Jian W; Qiu B; Wen J; Liu J; Fu B; Zhou X; Zhao T
Lung; 2016 Feb; 194(1):137-46. PubMed ID: 26608347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
